Adagene Inc. (China)

The Company, together with its subsidiaries, are principally engaged in research, development and production of monoclonal antibody drugs for cancers.
The Company is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Its platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by The Company s immunotherapy pipeline. These features enable its novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. The Company has pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. The Company aims to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology.
The Company operates and manages it business as a single segment.
HISTORY
2011 The Company is a limited liability company incorporated in the Cayman Islands on February 25, 2011.
In December 2011, the Company established Adagene (Hong Kong) Limited, or Adagene Hong Kong, a wholly-owned subsidiary incorporated under the laws of Hong Kong, as its intermediary holding company.
2017 In September 2017, the Company established a wholly-owned subsidiary in the state of Delaware, the United States, Adagene Incorporated, to conduct its research and development activities in the United States to facilitate the discovery and development of product candidates and expand its global presence, the Company has further incorporated several subsidiaries overseas, such as Australia, Singapore and Switzerland.
2021 The Company s ADSs have been listed on the Nasdaq Global Market since February 9, 2021 under the symbol “ADAG.”
2024 On March 29, 2024, the Company entered into a sales agreement with Leerink Partners LLC, under which the Company may offer and sell its ordinary shares in the form of ADSs, having aggregate gross proceeds of up to US 100.0 million, from time to time through it as its sales agent in its at-the-market equity offering program.